P2X3: a female-driven amplifier of mast cell activity
P2X3 is a Female-Dominant Amplifier of Mast Cell Function
This work looks at whether a protein called P2X3 makes allergic reactions stronger in women by boosting mast cell activity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11140333 on NIH RePORTER |
What this research studies
The researchers are examining why mast cells from females respond more strongly to allergic signals using experiments in mice, human mast cells grown in the lab, and animal models. They observed that the antidepressant fluoxetine suppresses mast cell activation in a female-specific way and appears to act on P2X3, an ATP-activated receptor. The team will test whether mast cells release ATP that triggers P2X3 in an autocrine loop and whether blocking P2X3 reduces allergic inflammation. These lab and preclinical studies aim to identify a druggable mechanism that could explain higher allergic asthma rates and severity in women.
Who could benefit from this research
Good fit: People with allergic diseases such as allergic asthma—particularly adult women—would be the most relevant candidates for participation or future trials.
Not a fit: People with non-allergic forms of disease, those without mast-cell driven allergies, or men may be less likely to benefit from therapies targeting this female-specific pathway.
Why it matters
Potential benefit: If successful, this work could lead to treatments that block P2X3 to reduce allergic inflammation, especially helping women with allergic asthma.
How similar studies have performed: P2X3 blockers have been studied in pain research, but using them to reduce mast cell–driven allergic inflammation is a new and largely untested approach.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Ryan, John J — Virginia Commonwealth University
- Study coordinator: Ryan, John J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.